AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01472653
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 30 mg/m2/week I.V. during radiotherapy
Trial: NCT01472653
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
Trial: NCT00868491
Drug: cetuximab, cisplatin
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)
Trial: NCT01544959
Drug: beta-blocker (esmolol, metropolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
Trial: NCT03338621
Drug: Pretomanid
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg tablets
Trial: NCT03338621
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg tablets
Trial: NCT03338621
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets
Trial: NCT03338621
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablets
Trial: NCT03338621
Drug: HRZE
RxNorm normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
Trial: NCT02533102
Drug: E7050
RxNorm normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet administered orally
Trial: NCT00697541
Drug: 0.18% COL-118 facial gel (1.8 mg brimonidine)
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
Trial: NCT00697541
Drug: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
Trial: NCT00697541
Drug: COL-118 facial gel vehicle
RxNorm normalized name: sulfur
DrugBank: Col-118 (DB05778)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
Trial: NCT03338621
Drug: HR
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isoniazid 75 mg plus rifampicin 150 mg combination tablets
Trial: NCT02484001
Drug: ESL 800 mg
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one (1) tablet of 800 mg (QD).
Trial: NCT02484001
Drug: ESL 1200 mg
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
Trial: NCT02484001
Drug: ESL 1600 mg
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two (2) tablets of 800 mg (QD).
Trial: NCT02484001
Drug: ESL 400 mg
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
Trial: NCT01859793
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg pill, administered once/day orally
Trial: NCT02784626
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative sedation using dexmedetomidine
Trial: NCT02784626
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative sedation using propofol
Trial: NCT00058968
Drug: Duloxetine hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: BIBR 1048 MS Capsule A
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: BIBR 1048 MS Capsule B
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: BIBR 1048 MS Capsule C
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: BIBR 1048 MS Capsule D
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: BIBR 1048 MS tartaric acid solution
RxNorm normalized name: Tartaric Acid
DrugBank: L-tartaric acid (DB09459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02170896
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02062710
Drug: diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
Trial: NCT02062710
Drug: diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
Trial: NCT02062710
Drug: dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
Trial: NCT02062710
Drug: dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
Trial: NCT02062710
Drug: placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
Trial: NCT02062710
Drug: placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
Trial: NCT03250481
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation targeted to RASS -3-0 or RI 20-40
Trial: NCT00326781
Drug: Nicotine Nasal Spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
Trial: NCT00508287
Drug: BMS-686117
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
Trial: NCT00508287
Drug: Byetta
RxNorm normalized name: Byetta
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
Trial: NCT03192995
Drug: lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lorcaserin 20 mg tablet
Trial: NCT02939300
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Melanoma:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.
Trial: NCT04514094
Drug: SDF
RxNorm normalized name: WinRho SDF
DrugBank: Human Rho(D) immune globulin (DB11597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
Trial: NCT03361865
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administered intravenously every 3 weeks.
Trial: NCT03361865
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat administered orally twice daily.
Trial: NCT02641886
Drug: Jian Pi Yi Shen Hua Tan Granules
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
Trial: NCT04169672
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Trial: NCT04169672
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Trial: NCT00079586
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
Trial: NCT02939300
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses
Trial: NCT04425018
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
Trial: NCT04425018
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Trial: NCT04425018
Drug: Margetuximab
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Trial: NCT04425018
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
Trial: NCT01950689
Drug: Nimorazole
RxNorm normalized name: nimorazole
DrugBank: Nimorazole (DB12172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637559
Drug: Esomeprazole Magnesium
RxNorm normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00275314
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01062165
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
Trial: NCT02173288
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02173288
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01424514
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg intra nasal
Trial: NCT00546117
Drug: lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
Trial: NCT03138733
Drug: Ceftobiprole medocaril
RxNorm normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
Trial: NCT03138733
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
Trial: NCT00946296
Drug: Potassium Iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
Trial: NCT03060798
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: general anesthesia using desflurane.
Trial: NCT03517423
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
Trial: NCT02237508
Drug: Z7200 without oral activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
Trial: NCT02304757
Drug: 99Tc-MDP
RxNorm normalized name: (99Tc)pertechnetate
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99Tc-MDP, H20000218
Trial: NCT02304757
Drug: Fosamax
RxNorm normalized name: Fosamax
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H20080172
Trial: NCT00088959
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02237508
Drug: Symbicort Turbohaler without oral activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
Trial: NCT00259766
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00259766
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00259766
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02542241
Drug: Sodium Chloride [3%]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Trial: NCT02237508
Drug: Z7200 with oral activated charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
Trial: NCT02237508
Drug: Symbicort Turbohaler with oral activated charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Trial: NCT02542241
Drug: Sodium Chloride [0.9%]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Trial: NCT04598451
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone tablets
Trial: NCT01323153
Drug: dalcetrapib
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of 600 mg once daily for 20 weeks
Trial: NCT00459004
Drug: rimonabant (SR141716)
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02775877
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02775877
Drug: clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04519788
Drug: AT-301B
RxNorm normalized name: AT-III
DrugBank: AT-301 (DB16507)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray
Trial: NCT04519788
Drug: AT-301A
RxNorm normalized name: AT-III
DrugBank: AT-301 (DB16507)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray
Trial: NCT05995691
Drug: ABP 501
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05995691
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC injection
Trial: NCT00003152
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003152
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04489849
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: apixaban 2.5mg BID for 3 months in experimental group
Trial: NCT03634436
Drug: SHR-1209
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Trial: NCT00101036
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03043157
Drug: rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous rocuronium infusion
Trial: NCT02872857
Drug: 8mg galantamine twice daily
RxNorm normalized name: galantamine 8 MG
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.
Trial: NCT02872857
Drug: 12mg galantamine twice daily
RxNorm normalized name: galantamine 12 MG
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.
Trial: NCT00393263
Drug: pimecrolimus and clobetasol
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no